FDA approves another at-home test
“FDA continues to authorize COVID-19 tests that will give more Americans access to greater testing flexibility and options,” FDA Commissioner Stephen M. Hahn said. “The BinaxNOW COVID-19 Ag Home Test will have a significant manufacturing footprint with the potential to support testing for millions of people.” Abbott expects to produce 30 million BinaxNOW at-home tests in the first quarter of 2021 and an additional 90 million in the second quarter. It requires a prescription, unlike the over-the-counter test from Ellume approved Tuesday. The Ellume test is a product of the RadX...
Source: washingtontimes.com